ProCE Banner Activity

BRCAAway: Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in HRR-Mutant Metastatic CRPC

Conference Coverage

Analysis from the phase II BRCAAway trial found that olaparib plus abiraterone/prednisone resulted in longer PFS and higher ORR vs olaparib or abiraterone/prednisone monotherapy in patients with mCRPC and BRCA1/2 or ATM mutations.

Released: January 30, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC